CN Patent

CN117500813A — 芳基氧膦类化合物

Assigned to Wigen Biomedicine Technology Shanghai Co Ltd · Expires 2024-02-02 · 2y expired

What this patent protects

一类芳基氧膦类化合物。具体的，涉及一类通式(1)所示的化合物及其制备方法，及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐作为EGFR抑制剂在抗肿瘤等EGFR相关疾病的药物制备中的用途。

USPTO Abstract

一类芳基氧膦类化合物。具体的，涉及一类通式(1)所示的化合物及其制备方法，及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐作为EGFR抑制剂在抗肿瘤等EGFR相关疾病的药物制备中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117500813A
Jurisdiction
CN
Classification
—
Expires
2024-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.